Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development

American Journal of Tropical Medicine and Hygiene

Volumn 88, Issue 5, 2013, Pages 962-970

  Timiryasova, Tatyana M ^a   Bonaparte, Matthew I ^a   Luo, Ping ^a   Zedar, Rebecca ^a   Hu, Branda T ^a   Hildreth, Stephen W ^a  

^a SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE; DENGUE VACCINE; NEUTRALIZING ANTIBODY;

ACCURACY; ANIMAL CELL; ANTIBODY DETECTION; ARTICLE; ASSAY; DENGUE; DENGUE VIRUS; HUMAN; INCUBATION TEMPERATURE; NONHUMAN; QUANTITATIVE ANALYSIS; SERODIAGNOSIS; SEROTYPE; SERUM; VALIDATION STUDY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; NEUTRALIZATION TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEROTYPING; VIRAL PLAQUE ASSAY;

DENGUE VIRUS;

EID: 84877122889     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.12-0461     Document Type: Article

References (47)

1. Gubler DJ, 2002. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10: 100-103. (Pubitemid 34119347)
2. Lindenbach BD, Rice CM, 2003. Molecular biology of flaviviruses. Adv Virus Res 59: 23-61. (Pubitemid 137639363)
3. World Health Organization Regional Office for South-East Asia, 2011. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever. Available at: http://www.searo.who.int/LinkFiles/Dengue-DHF- prevention&control-guidelines-rev.pfd.
4. Thomas SJ, Endy TP, 2011. Vaccines for the prevention of dengue: development update. Hum Vaccin 7: 674-684.
5. Murphy BR, Whitehead SS, 2011. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29: 587-619.
6. Clarke DH, Casals J, 1958. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 7: 561-573.
7. Centers for Disease Control, 1981. A Guide to the Performance of the Standardized Diagnostic Complement Fixation Method and Adaptation to Micro Test. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control.
8. Casey HL, 1965. Standardized diagnostic complement fixation method and adaptation to micro test. Public Health Monogr 74: 1-34.
9. Chungue E, Marche G, Plichart R, Boutin JP, Roux J, 1989. Comparison of immunoglobulin G enzyme-linked immunosorbent assay (IgG-ELISA) and haemagglutination inhibition (HI) test for the detection of dengue antibodies. Prevalence of dengue IgG-ELISA antibodies in Tahiti. Trans R Soc Trop Med Hyg 83: 708-711. (Pubitemid 19252154)
10. Miagostovich MP, Nogueira RM, dos Santos FB, Schatzmayr HG, Araujo ES, Vorndam V, 1999. Evaluation of an IgG enzyme-linked immunosorbent assay for dengue diagnosis. J Clin Virol 14: 183-189.
11. Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, Puttisri P, Hoke CH, 1989. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 40: 418-427. (Pubitemid 19117542)
12. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP, 2009. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 81: 825-833.
13. Russell PK, Nisalak A, Sukhavachana P, Vivona S, 1967. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 99: 285-290.
14. Putnak JR, de la Barrera R, Burgess T, Pardo J, Dessy F, Gheysen D, Lobet Y, Green S, Endy TP, Thomas SJ, Eckels KH, Innis BL, Sun W, 2008. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg 79: 115-122. (Pubitemid 351957214)
15. Roehrig JT, Hombach J, Barrett AD, 2008. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21: 123-132. (Pubitemid 351873374)
16. Yoksan S, Tubthong K, Kanitwithayanun W, Jirakanjanakit N, 2009. Laboratory assays and field dengue vaccine evaluation at Ratchaburi province, Thailand: a preliminary result. J Clin Virol 46 (Suppl 2): S13-S15.
17. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N, 1985. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22: 250-254. (Pubitemid 15006964)
18. World Health Organization, 2007. Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses. WHO/IVB/07.07. Available at: http://whqlibdoc.who.int/hq/2007/who-ivb-07.07-eng.pdf.
19. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J, 2011. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29: 7229-7241.
20. Lang J, 2009. Recent progress on Sanofi Pasteur's dengue vaccine candidate. J Clin Virol 46 (Suppl 2): S20-S24.
21. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W, 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69 (Suppl 6):48-60.
22. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L, Saluzzo JF, Bhamarapravati N, 2004. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23: 99-109. (Pubitemid 38222779)
23. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, Jagsudee A, Saluzzo JF, Bhamarapravati N, 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66: 264-272. (Pubitemid 34756095)
24. Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak JR, Eckels KH, Hutagalung Y, Gibbons RV, Zhang C, De La Barrera R, Jarman RG, Chawachalasai W, Mammen MP Jr, 2008. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 78: 426-433. (Pubitemid 351845193)
25. International Conference on Harmonization, 1995. Guidance for Industry: Validation of Analytical Procedures. Document Q2A. Available at: http://www.fda.gov/cder/guidance/ichq2a.pdf.
26. International Conference on Harmonization, 1996. Guidance for Industry: Validation of Analytical Procedures. Document Q2B. Available at: http://www.fda.gov/cder/guidance/ichq2b.pdf.
27. Food and Drug Administration, 2001. Guidance for Industry: Bioanalytical Method Validation. Available at: http://www.fda.gov/cder/guidance/4252fnl.pdf.
28. Guy B, Chanthavanich P, Gimenez S, Sirivichayakul C, Sabchareon A, Begue S, Yoksan S, Luxemburger C, Lang J, 2004. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 22: 3563-3574. (Pubitemid 39099632)
29. Mota J, Acosta M, Argotte R, Figueroa R, Mendez A, Ramos C, 2005. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23: 3469-3476. (Pubitemid 40517122)
30. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP, 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75: 7290-7304. (Pubitemid 32737987)
31. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP, 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74: 5477-5485. (Pubitemid 30346579)
32. Sithisarn P, Suksanpaisan L, Thepparit C, Smith DR, 2003. Behavior of the dengue virus in solution. JMed Virol 71: 532-539. (Pubitemid 37309924)
33. Morens DM, Halstead SB, Larsen LK, 1985. Comparison of dengue virus plaque reduction neutralization by macro and "semi-micro" methods in LLC-MK2 cells. Microbiol Immunol 29: 1197-1205. (Pubitemid 16190464)
34. Matsumura T, Stollar V, Schlesinger RW, 1972. Effects of ionic strength on the release of dengue virus from Vero cells. J Gen Virol 17: 343-347.
35. Brandler S, Brown N, Ermak TH, Mitchell F, Parsons M, Zhang Z, Lang J, Monath TP, Guirakhoo F, 2005. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg 72: 74-81. (Pubitemid 41270311)
36. Gupta CK, Leszczynski J, Gupta RK, Siber GR, 1996. Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 14: 1417-1420. (Pubitemid 27008256)
37. Hunter-Cevera JC, Belt A, 1996. Maintaining Cultures for Biotechnology and Industry. San Diego, CA: Academic Press.
38. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB, 1984. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653-569.
39. Endy TP, Nisalak A, Chunsuttiwat S, Libraty DH, Green S, Rothman AL, Vaughn DW, Ennis FA, 2002. Spatial and temporal circulation of dengue virus serotypes: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 156: 52-59. (Pubitemid 34680623)
40. Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I, 2010. Discrepancy in dengue virus neutralizing antibody titers between plaque reduction neutralizing tests with Fcgamma receptor (FcgammaR)-negative and FcgammaR-expressing BHK-21 cells. Clin Vaccine Immunol 17: 402-407.
41. Beaty BJ, Calisher CH, Shope RE, 1995. Arboviruses. In: Leanette EH, Schmidt NJ, eds. Diagnostic Procedures for Viral, Rickettsial and Chyamydial Infections. Seventh edition. American Public Health Association, 189-212.
42. Martin NC, Pardo J, Simmons M, Tjaden JA, Widjaja S, Marovich MA, 2006. An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies. J Virol Methods 134: 74-85.
43. Kraus AA, Messer W, Haymore LB, de Silva AM, 2007. Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 45: 3777-3780. (Pubitemid 350156883)
44. Vorndam V, Beltran M, 2002. Enzyme-linked immunosorbent assay-format microneutralization test for dengue viruses. Am J Trop Med Hyg 66: 208-212. (Pubitemid 34755655)
45. Ting SH, See E, Tan HC, Lee MA, Ooi EE, 2001. Development of a simplified assay for the detection of neutralizing antibodies to Japanese encephalitis virus. J Virol Methods 93: 43-47. (Pubitemid 32322513)
46. Jirakanjanakit N, Sanohsomneing T, Yoksan S, Bhamarapravati N, 1997. The micro-focus reduction neutralization test for determining dengue and Japanese encephalitis neutralizing antibodies in volunteers vaccinated against dengue. Trans R Soc Trop Med Hyg 91: 614-617. (Pubitemid 27478663)
47. Thacker WL, Lewis VJ, Baer GM, Sather GE, 1978. A rapid fluorescent focus-inhibition test for determining dengue neutralizing antibody and for identifying prototype dengue viruses. Can J Microbiol 24: 1553-1556. (Pubitemid 9102315)